What is the standard treatment and laboratory follow‑up for central and nephrogenic diabetes insipidus?

Standard Treatment and Laboratory Follow-Up for Diabetes Insipidus

Nephrogenic Diabetes Insipidus (NDI)

For symptomatic infants and children with NDI, start treatment with a thiazide diuretic combined with prostaglandin synthesis inhibitors (NSAIDs), alongside dietary modifications including salt and protein restriction 1.

Pharmacological Treatment

Initial therapy:

• Thiazide diuretics (e.g., hydrochlorothiazide) combined with prostaglandin synthesis inhibitors (COX inhibitors like indomethacin)
• This combination can reduce urine output by up to 50% in the short term when paired with a low-salt diet 1
• The mechanism involves mild volume depletion increasing proximal sodium and water reabsorption 1

Important caveat: Drug treatment can be highly effective in infancy, with reported cases of marked hyponatremia when patients maintain high fluid intake after starting medications. Close monitoring of fluid balance, weight, and biochemistry is mandatory at treatment initiation 1.

Medication adjustments:

• Add amiloride if thiazide-induced hypokalaemia develops 1
• Discontinue COX inhibitors at age ≥18 years or earlier if full continence is achieved, due to nephrotoxicity concerns 1
• Thiazide diuretics may be continued into adulthood if preferred (hydrochlorothiazide 25 mg once or twice daily) 1

Dietary Management

Salt and protein restriction (age-specific recommendations from 1):

Age	Salt	Protein
0-1 year	1 g/day (0.4 g sodium)	1.3-1.8 g/kg/day
1-3 years	2 g/day (0.8 g sodium)	1.1 g/kg/day
4-6 years	3 g/day (1.2 g sodium)	0.95 g/kg/day
7-10 years	5 g/day (2 g sodium)	0.95 g/kg/day
>11 years	<6 g/day (2.4 g sodium)	0.85 g/kg/day
Adults	<6 g/day (2.4 g sodium)	<1 g/kg/day

Critical principle: Excessive restriction can compromise growth 1

Nutritional Support

• Free access to fluid at all times 1
• Normal-for-age milk intake (not water) in infants to ensure adequate calories 1
• Consider tube feeding (nasogastric or gastrostomy) if repeated vomiting/dehydration episodes or failure to thrive occur 1
• Approximately 20-30% of children require tube feeding at some point, rarely continued beyond age 4 years 1

Laboratory Follow-Up

Treatment efficacy monitoring 1:

• Urine osmolality
• Urine output measurement
• Weight gain and growth parameters
• Serum sodium, serum osmolality
• Electrolytes (particularly potassium if on thiazides)

Imaging surveillance:

• Kidney ultrasound at least every 2 years to monitor for urinary tract dilatation and/or bladder dysfunction from polyuria 1
• Hydronephrosis occurs in approximately 34% of NDI patients 1

Multidisciplinary Care

Required team members 1:

• (Paediatric) nephrologist
• Dietitian experienced with NDI
• Psychologist
• Social worker
• Urologist

---

Central Diabetes Insipidus (CDI)

For central diabetes insipidus, desmopressin (synthetic ADH analogue) is the primary treatment 2, 3, 4.

Pharmacological Treatment

Desmopressin administration:

• Available as oral, intranasal, or subcutaneous formulations
• Dosing must be individualized based on response
• Monitor for hyponatremia risk - the most significant treatment complication 4

Key monitoring principle: Unlike NDI, CDI patients can concentrate urine with desmopressin, making water intoxication and hyponatremia a real danger if fluid intake is not appropriately adjusted 4.

Laboratory Follow-Up

Essential monitoring:

• Serum sodium levels (primary concern is hyponatremia from overtreatment)
• Serum osmolality
• Urine osmolality and output
• Fluid balance assessment

Diagnostic confirmation (if not already done):

• Water deprivation test followed by desmopressin administration remains the gold standard 2, 5
• Copeptin measurement (surrogate marker for AVP) shows promise for improved diagnostic accuracy 4, 5

Etiological Investigation

Once CDI is biochemically confirmed, investigate the underlying cause 4:

• MRI of pituitary/hypothalamus
• Assessment for infiltrative diseases, tumors, trauma, or genetic causes
• The etiology determines long-term prognosis and additional management needs

---

Common Pitfalls to Avoid

1. Starting medications in NDI without close initial monitoring - can precipitate severe hyponatremia 1
2. Restricting salt/protein excessively - compromises growth in children 1
3. Continuing COX inhibitors into adulthood - nephrotoxicity risk 1
4. Overtreatment of CDI with desmopressin - leads to water intoxication and hyponatremia 4
5. Failing to perform regular renal ultrasounds in NDI - misses progressive hydronephrosis 1